Because precocious pubarche (PP) reveals late-onset congenital adrenal hyperplasia (LO-CAH) in 5 to 20% of cases, an adrenal stimulation test is recommended in all patients presenting with it. This test is stressful and expensive, and results are normal in more than 80% of cases.
P
recocious pubarche (PP) is defined as pubic hair onset before age 8 in girls and age 9 in boys (1) (2) (3) (4) (5) . In 80 to 95% of cases, PP is related to premature adrenarche (PA), the nonpathological precocious secretion of adrenal androgens (6, 7) . In 5 to 20% of cases, however, the cause of PP is late-onset congenital adrenal hyperplasia (LO-CAH) (3-5, 8 -16) , which is due mainly to nonclassic 21-hydroxylase deficiency, a mild adrenal enzyme defect related to a CYP21 gene mutation that causes excessive androgen secretion (3, (17) (18) (19) . LO-CAH is a rare but potentially severe condition. If not promptly diagnosed, it can lead to accelerated bone maturation (4), short final height (20) , and in adulthood to severe cystic acne (20, 21) , hirsutism (22) , and hypofertility (23, 24) . Early identification of LO-CAH makes it possible to administer substitution therapy that controls symptoms related to androgen excess (4, 11, 12, 16, (25) (26) (27) . LO-CAH is currently diagnosed by abnormal hormonal response after an adrenal stimulation test with synthetic ACTH (2, 3, 17) , specifically an elevated plasma level of ACTH-stimulated 17-hydroxyprogest-erone (17-OHP) (28) . This test requires day-hospitalization in a specialized unit, as well as repeated blood sampling, which is distressing and expensive.
Previous studies and guidelines present widely varying indications for ACTH tests in patients with PP. Given that no clinical feature predicts LO-CAH well and that PP may be its earliest manifestation, many consider that an ACTH test should be performed in all children with PP to verify the absence of LO-CAH (4, 5, 9, 10, 12, 13, 15, 16, 26, 27) . The application of this systematic strategy assures 100% sensitivity for diagnosing LO-CAH but produces normal ACTH tests in more than 80% of patients. A posteriori these tests are thus unnecessary. Other authors suggest a selective approach toward ACTH tests for patients with "high" basal 17-OHP (5, 8, 12, 13, 16, 26, 28, 29) or ⌬4-androstenedione (⌬4A) plasma levels (16, 28) or with a dehydroepiandrosterone/⌬4A ratio greater than 1 (13) . However, the predictive value of these thresholds has never been tested in children with PP (5, 12-14, 16, 28, 29) .
The identification of a highly sensitive and quite specific selective approach to prescription of ACTH tests in patients with PP would make it possible to avoid a posteriori unnecessary normal tests without missing any patient with LO-CAH. The aim of our study was to identify clinical and plasma predictors of LO-CAH and to test their predictive value in children with PP.
Patients and Methods
We conducted a retrospective hospital-based cohort study. The study included all patients seen for PP in the pediatric endocrinology unit of a teaching hospital in Paris (France) between 1999 and 2006, unless they met the exclusion criteria described below. They were identified by checking computerized hospital charts for the term "precocious pubarche" and reviewing a local clinical register. During the study period, the local protocol required the systematic prescription of an ACTH test for all patients seen for PP. PP was defined as pubic hair onset before age 8 in girls and age 9 in boys (1) (2) (3) (4) (5) . Patients were excluded if they had concomitant clinical signs of central puberty (breast development before age 8 in girls or testicular development before age 9 in boys) (5, 8, 15, 16) or signs of adrenal tumors (rapidly progressive systemic virilization) or hypercorticism (Cushing's syndrome) (5, 10) . The patients lost to follow-up before an ACTH test was performed were secondarily excluded. The Institutional Review Committee (Comité de Protection des Personnes Ile de France III) stated that "this research was found to conform to generally accepted scientific principles and research ethical standards and to be in conformity with the laws and regulations of France, where the research experiment was performed." Written informed consent of the patients or their parents was not judged necessary for this kind of retrospective study.
Patients were considered to have LO-CAH if their stimulated 17-OHP plasma level was equal to or greater than 10 ng/ml; otherwise, the patients were considered to have PA (4, 5, 8 -10, 12-14, 16, 26 -28) . The diagnosis of all patients determined to have LO-CAH was confirmed by mutational analysis of the CYP21 gene (18) .
We considered as potential predictors all clinical and basal hormonal variables available at the time of the first medical examination in our center with a missing data rate lower than 15%. The potential clinical predictors were sex, age at pubic hair onset as reported by the patient or her/his parents (years), weight (SD), height (SD), body mass index (BMI; percentiles), and Tanner stage for pubic hair as recorded at the first physical examination (30 -32) . The potential plasma predictors were basal plasma levels of 17-OHP, ⌬4A, testosterone, and 11-deoxycortisol, reported in nanograms per milliliter. The ACTH test was performed as internationally recommended: a basal blood sample at 0800 h immediately followed by im infusion of 0.25 mg of tetracosactide acetate (Synacthen) and another blood sample 60 min after the infusion. The basal blood sample included the baseline measurement of serum 17-OHP. A single laboratory measured 17-OHP, ⌬4A, and testosterone by radioimmunological assays (OHP-CT: Cis Bio, Gif-sur-Yvette, France; ⌬4A RIA: Immunotech, Marseille, France; and Testo-CT2: Cis Bio, Gifsur-Yvette, France). Plasma levels of 11-deoxycortisol were measured with the combined RIA developed at Saint-Louis Hospital (Paris). The same kit was used for each potential predictor throughout the study period.
We first described the general characteristics of the study population and compared the distributions of the continuous potential predictors between patients with LO-CAH and PA with the nonparametric MannWhitney test. The discriminating power of the potential predictors was evaluated by comparing the areas under receiver-operating characteristic (ROC) curves according to the standard method described by Hanley and McNeil (33) . Continuous variables were dichotomized according to either a cutoff value reported in the literature (14, 29) or their distribution among the patients without LO-CAH. Weight, height, and BMI as recorded at the first medical examination were dichotomized around a threshold set at ϩ2 SD (height and weight) or the 97th percentile (BMI) above the mean (or median) value for age and sex; Tanner stage for pubic hair was dichotomized around stage II to offer the best clinical reproducibility. We studied the relations between LO-CAH and the dichotomized potential predictors with a univariate analysis and calculated the odds ratios (OR). Distributions were compared with Fisher's exact test.
We looked for an interaction of sex in the relation between the age at pubic hair onset and the diagnosis of LO-CAH because PP is defined at different ages in boys and girls. The predictive value of each potential predictor was evaluated by calculating its sensitivity, specificity, positive and negative predictive values (PPV, NPV), and the likelihood ratios (LR) for a positive and a negative test (LRϩ, LRϪ). The 95% confidence intervals (CIs) were calculated with a binomial approximation (34) . If a table contained an empty cell, a corrected OR was calculated by adding a 0.5 value in each cell of the table (35) . Because of the very unbalanced distribution of the main plasma predictor, we did not adjust for other variables (for example, by using a logical regression model). All statistical analyses were performed with STATA/SE 9 software (Statacorp, College Station, TX).
Results
During the study period, 372 patients were seen for PP, 99 (27%) of them met the same exclusion criterion: signs of central puberty concomitant to pubic hair onset. None met either of the other two exclusion criteria, but 35 (13%) of the remaining 273 patients were lost to follow-up before an ACTH test. The analysis was thus based on 238 patients, 75% of them girls. Overall, median age at pubic hair onset was 6.6 yr (mean, 5.9; range, 0.1-8.9). Among girls, median age at pubic hair onset was 6. No statistically significant difference was observed between the distributions of the following clinical variables in patients with LO-CAH and PA: age at pubic hair onset, weight, height, and pubic hair Tanner stage at the time of the first medical examination in our center (Table 1) . A trend toward a statistically significant difference was observed between the distributions of BMI among patients with LO-CAH and with PA (median, 1.03 vs. 0.80; P ϭ 0.09). No statistically significant difference was observed in the distribution of 11-deoxycortisol plasma levels between the two groups. Basal plasma levels of 17-OHP, ⌬4A, and testosterone were all significantly higher (P Յ 0.001) in patients with LO-CAH than in those with PA (Table 1 and Fig. 1 ). The areas under the ROC curves (AUC) for 17OHP, ⌬4A, and testosterone were 0.99 (95% CI, 0.98 -1.00), 0.90 (95% CI, 0.81-1.00), and 0.83 (95% CI, 0.69 -0.98), respectively. The AUC for 17-OHP was statistically significantly larger than the AUC of all other predictors (P Յ 0.05; Fig. 2 ).
After dichotomization, no statistically significant association was observed between the diagnosis of LO-CAH and the following clinical variables: male sex, age at pubic hair onset no greater than 6 yr, weight more than ϩ2 SD, height more than ϩ2 SD, and Tanner stage for pubic hair above stage II at first examination (Table 2) . A trend toward a statistically significant association was observed between a BMI above the 97th percentile and the diagnosis of LO-CAH (OR, 3.7; 95% CI, 1.1-13; P ϭ 0.07). We found no interaction of sex in the relation between the age at pubic hair onset and LO-CAH (P ϭ 0.53).
A basal 17-OHP plasma level greater than 2 ng/ml offered 100% (95% CI, 69 -100) sensitivity for predicting LO-CAH, and 99% (95% CI, 97-100) specificity. None of the other plasma predictors considered alone had a better predictive power than basal 17-OHP plasma level. The discriminating power of the three plasma predictors was not improved when the distributions were dichotomized around other thresholds (Table 3) .
Discussion
We describe the largest cohort of children seen for PP thus far reported because all previously published studies had smaller samples (IQR, 15-55; range, 9 -171) (5, 8 -12, 14 -16, 26, 27) . In contrast to some reports that patients with LO-CAH, compared with those with PA, are taller, heavier, or have accelerated bone maturation (5, 8, 16) , our study did not identify any clinical predictor of LO-CAH; only BMI tended to be distributed differentially between patients with LO-CAH and with PA. We identified three plasma predictors of LO-CAH in children with PP: high basal 17-OHP, ⌬4A, and testosterone plasma levels. The basal 17-OHP plasma level is often reported to be elevated in patients with LO-CAH and has previously been suggested as a good predictor (8, 12-14, 16, 26, 27) . Levine et al. (13) suggested that a basal 17-OHP plasma level above 5 ng/ml combined with a dehydroepiandrosterone/⌬4A ratio above 1 was a good predictor of LO-CAH. Ibáñ ez et al. proposed that a basal 17-OHP plasma level above ϩ2 SD was indicative of LO-CAH in patients with PP (26) . None of these studies, however, analyzed the discriminating power of these predictors statistically. Clinicians who must decide which patients should undergo an ACTH test require decision-making aid, and this can be obtained only by precise and statistically tested thresholds. We set a basal 17-OHP plasma level threshold at 2 ng/ml to obtain the best sensitivity and specificity. The relevance of this threshold can also be appreciated by comparison to the reference nomogram published by New et al. (28) . In the population of this historical study, our threshold would have had 100% sensitivity and specificity. It is also the same as that proposed and prospectively validated by Azziz et al. (29) in a population of unselected hyperandrogenic women. In their study population, where LO-CAH prevalence was 8%, they showed that a basal 17-OHP plasma level below 2 ng/ml effectively ruled out LO-CAH with 100% sensitivity and 99% specificity; the PPV was 80%, and the NPV was close to 100%. In our cohort, where the prevalence of LO-CAH was 4%, the NPV of a basal 17-OHP plasma level below 2 ng/ml was 100% (95% CI, 98 -100%). A clinician could have safely ruled out LO-CAH in any PP patient in our cohort with a basal 17-OHP plasma level below 2 ng/ml. Because hormonal measurements are highly assay-specific, we may consider the percentile of our threshold value (94th percentile of the distribution of basal 17-OHP plasma levels in the group of patients with PA) to allow standardized comparison with the results obtained with other assays, as proposed for other predictive tools in pediatric endocrinology (36) . Basal ⌬4A and testosterone plasma levels have previously been proposed as potential predictors of LO-CAH, but their predictive values have never been statistically determined (5, 13, 14, 16) . In our cohort, a basal ⌬4A plasma level above 0.95 ng/ml or a basal testosterone plasma level above 0.15 ng/ml was strongly and significantly associated with a LO-CAH diagnosis (Table 3 ). However, their predictive power was lower than that of 17-OHP.
We tried to include all consecutive patients seen for PP at our center during the study period. Given the retrospective design of our study, a classification bias was possible. It is likely, however, that any such bias is weak for all patients were examined by the same physician and stringent exclusion criteria were applied (i.e. exclusion of patients with signs of central puberty). Many of the boys also underwent an LHRH test after the ACTH test to rule out central precocious puberty before an increase in testicular volume. The collection of all blood samples at regular times for basal and stimulated levels and their processing according to standardized protocols in the laboratory limited another source of classification bias (37) . Relatively few patients were lost to follow-up (n ϭ 35; 13%), and the distributions of gender and age at pubic hair onset did not differ between this group and the patients included in our cohort (P Ͼ 0.30). Selection bias is thus unlikely.
The retrospective design of the study resulted in missing data rates greater than 15% for potentially relevant data (growth velocity, advance in bone age, basal ACTH and dehydroepiandrosterone sulfate plasma levels) and their exclusion from the analyses. Nonetheless, none of these indicators has been suggested as a predictor of LO-CAH in the literature. Many clinicians believe bone age advance is greater in patients with LO-CAH than in those with PA, a belief supported by the analysis of our available data (63% of our patients, including 10 patients with LO-CAH): median standardized bone age, ϩ 2.0 vs. ϩ 0.6 yr (P ϭ 0.001). Of the plasma predictors we did assess, the highest missing data rate (3%) concerned the basal testosterone plasma level. Nonetheless, when we used the maximum bias hypothesis, the association between a basal testosterone plasma level above 0.15 ng/ml and a diagnosis of LO-CAH remained strong and statistically significant (OR ϭ 6.1; 95% CI, 1.7-22; P Ͻ 0.01).
Although classification bias for LO-CAH in our study is possible, it is improbable because mutation analysis was used to confirm all LO-CAH diagnoses (18) . Moreover, we reduced the risk of interindividual variance in interpretation by using the same kit for each plasma predictor throughout the study period. Some other extremely rare causes of LO-CAH must be discussed. LO-CAH due to 11␤-hydroxylase deficiency has been reported to induce PP (38) . This diagnosis was genetically confirmed in one patient included in our cohort. Although 11␤-hydroxylase and 21-hydroxylase deficiencies are different diseases, she would nonetheless have been correctly identified with our selective approach because her basal 17-OHP plasma level was 3.7 ng/ml. Excluding her from the analysis did not significantly modify either the sensitivity (100%; 95% CI, 69 -100) or the NPV (100%; 95% CI, 98 -100) of our main predictor. Some authors suggest that PP may reveal childhood adrenal tumors (39) , which usually induce marked clinical signs of rapidly progressive systemic virilization. Because none of our patients presented these signs at their first medical examination, ultrasound imaging of the adrenals was not performed. Moreover, the median period of clinical follow-up-3.7 yr in our cohort (range, 1.2-14.3)-allowed us to rule out the presence of adrenal tumors among our patients presenting with PP.
A selection bias is possible because our patients were recruited through a highly specialized pediatric endocrinology outpatient department. It is likely, however, to be relatively weak because the prevalence of LO-CAH in our cohort was 4%, lower than any of the previously reported rates, which range from 5 to 43% (median, 8%) (5, 8, 9, 12, 14 -16, 26, 27) . Moreover, our observed sex ratio (0.33) was consistent with previous reports in smaller cohorts (median, 0.2; range, 0.0 -0.4) (5, 8, 9, 12, 14 -16, 26, 27) .
We identified three plasma predictors among patients with PP that are strongly and significantly associated with LO-CAH. These results can be integrated into a highly sensitive and specific structured strategy (40) usable in daily practice to limit unnecessary ACTH testing, which remains a stressful and costly procedure. In our cohort, according to our strategy, 99% of ACTH tests could have been safely avoided in patients presenting with PP. Such an evidence-based strategy could represent an alternative to the systematic approach that is currently proposed (9, 15, 16, 26) or to a selective approach based on unvalidated predictors (5, 8, 12, 27) . Because these findings come from a retrospective cohort from a single hospital, they must be prospectively validated to confirm their relevance before any clinical application (36) .
